These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 23419373)

  • 1. Cerebrospinal fluid biomarkers in Parkinson disease.
    Parnetti L; Castrioto A; Chiasserini D; Persichetti E; Tambasco N; El-Agnaf O; Calabresi P
    Nat Rev Neurol; 2013 Mar; 9(3):131-40. PubMed ID: 23419373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.
    Shi M; Bradner J; Hancock AM; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Kim HM; Leverenz JB; Montine TJ; Ginghina C; Kang UJ; Cain KC; Wang Y; Aasly J; Goldstein D; Zhang J
    Ann Neurol; 2011 Mar; 69(3):570-80. PubMed ID: 21400565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.
    Herbert MK; Eeftens JM; Aerts MB; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Parkinsonism Relat Disord; 2014 Jan; 20(1):112-5. PubMed ID: 24075122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.
    Shi M; Furay AR; Sossi V; Aasly JO; Armaly J; Wang Y; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Leverenz JB; Stoessl AJ; Zhang J
    Neurobiol Aging; 2012 Apr; 33(4):836.e5-7. PubMed ID: 22019052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.
    Waragai M; Sekiyama K; Sekigawa A; Takamatsu Y; Fujita M; Hashimoto M
    Int J Mol Sci; 2010 Oct; 11(11):4257-66. PubMed ID: 21151436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.
    Farotti L; Paciotti S; Tasegian A; Eusebi P; Parnetti L
    Expert Rev Mol Diagn; 2017 Aug; 17(8):771-780. PubMed ID: 28604235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.
    Hong Z; Shi M; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Leverenz JB; Baird G; Montine TJ; Hancock AM; Hwang H; Pan C; Bradner J; Kang UJ; Jensen PH; Zhang J
    Brain; 2010 Mar; 133(Pt 3):713-26. PubMed ID: 20157014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical premotor biomarkers for Parkinson's disease.
    Mollenhauer B; Zhang J
    Mov Disord; 2012 Apr; 27(5):644-50. PubMed ID: 22508282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems associated with fluid biomarkers for Parkinson's disease.
    Nyhlén J; Constantinescu R; Zetterberg H
    Biomark Med; 2010 Oct; 4(5):671-81. PubMed ID: 20945980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
    Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
    PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
    Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L
    JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease.
    Waragai M; Wei J; Fujita M; Nakai M; Ho GJ; Masliah E; Akatsu H; Yamada T; Hashimoto M
    Biochem Biophys Res Commun; 2006 Jul; 345(3):967-72. PubMed ID: 16707095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
    Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of biomarkers and imaging in Parkinson's disease.
    Algarni MA; Stoessl AJ
    Expert Rev Neurother; 2016; 16(2):187-203. PubMed ID: 26829357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson disease: Progress towards a molecular biomarker for Parkinson disease.
    Foulds P; Mann DM; Mitchell JD; Allsop D
    Nat Rev Neurol; 2010 Jul; 6(7):359-61. PubMed ID: 20639912
    [No Abstract]   [Full Text] [Related]  

  • 20. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
    Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.